Identification of PTGR2 inhibitors as a new therapy for diabetes and obesity

Abstract excerpt

Peroxisome proliferator-activated receptor γ (PPARγ) is a master transcriptional regulator of systemic insulin sensitivity and energy balance. The anti-diabetic drug thiazolidinediones (TZDs) are potent synthetic PPARγ ligands with undesirable side effects, including obesity, fluid retention, and osteoporosis. 15-keto prostaglandin E2 (15-keto-PGE2) is an endogenous PPARγ ligand metabolized by prostaglandin reduct...

Topics

Open a Topic to create a Post that cites this publication.

• Adipose Tissue
• Atherosclerosis
• Binding Sites
• Diabetes, Gestational
• Disease Models, Animal
• Mutation
• Peroxisome Proliferator-Activated Receptors
• Pregnancy

Identifiers and source

Literature Corpus work

a3a82b88-6668-5ec3-a43b-7426ca0e445f

DOI

10.1101/2024.12.17.629058